MedImmune Ltd

Active trials

• phase2COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCactive not recruitingn=61
• phase2A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinomaactive not recruitingn=433
• phase1A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumorsactive not recruitingn=400
• phase2Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Studyactive not recruitingn=43
• phase2Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesotheliomaactive not recruitingn=571
• phase1A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinomaactive not recruitingn=67
• phase2A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumorsactive not recruitingn=383
• —A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Ageterminatedn=4,121